Renaissance Technologies (RenTech)'s OCUL Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 1.15 M shares of Ocular Therapeutix, Inc. (OCUL) worth $9.72 M, representing 0.02% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 27 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in OCUL, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 791,200 shares. Largest reduction occurred in Q3 2025, reducing 410,048 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Ocular Therapeutix (OCUL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ocular Therapeutix (OCUL) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +356,782 | Add 45.09% | 1.15 M | $8.47 |
| Q4 2025 | +791,200 | New Buy | 791,200 | $12.14 |
| Q3 2025 | -410,048 | Sold Out | 0 | $0.00 |
| Q2 2025 | -43,952 | Reduce 9.68% | 410,048 | $9.28 |
| Q1 2025 | +454,000 | New Buy | 454,000 | $7.33 |
| Q2 2024 | -29,700 | Sold Out | 0 | $0.00 |
| Q1 2024 | +29,700 | New Buy | 29,700 | $9.09 |
| Q4 2023 | -125,200 | Sold Out | 0 | $0.00 |
| Q3 2023 | +100,307 | Add 402.95% | 125,200 | $3.14 |
| Q2 2023 | -46,300 | Reduce 65.03% | 24,893 | $0.01 |
| Q1 2023 | -222,800 | Reduce 75.78% | 71,193 | $0.01 |
| Q4 2022 | +279,200 | Add 1887.38% | 293,993 | $0.00 |
| Q3 2022 | -366,707 | Reduce 96.12% | 14,793 | $4.12 |
| Q2 2022 | -129,305 | Reduce 25.31% | 381,500 | $4.02 |
| Q1 2022 | +430,705 | Add 537.71% | 510,805 | $4.95 |
| Q4 2021 | -166,100 | Reduce 67.47% | 80,100 | $6.97 |
| Q3 2021 | -80,922 | Reduce 24.74% | 246,200 | $10.00 |
| Q2 2021 | +277,222 | Add 555.56% | 327,122 | $14.18 |
| Q1 2021 | -284,166 | Reduce 85.06% | 49,900 | $16.41 |
| Q4 2020 | +334,066 | New Buy | 334,066 | $20.70 |
| Q2 2017 | -88,900 | Sold Out | 0 | $0.00 |
| Q1 2017 | -56,200 | Reduce 38.73% | 88,900 | $9.28 |
| Q4 2016 | +145,100 | New Buy | 145,100 | $8.37 |
| Q3 2016 | -47,300 | Sold Out | 0 | $0.00 |
| Q2 2016 | +47,300 | New Buy | 47,300 | $4.95 |
| Q3 2015 | -10,992 | Sold Out | 0 | $0.00 |
| Q2 2015 | +10,992 | New Buy | 10,992 | $21.02 |
Renaissance Technologies (RenTech)'s Ocular Therapeutix Investment FAQs
Renaissance Technologies (RenTech) first purchased Ocular Therapeutix, Inc. (OCUL) in Q2 2015, acquiring 10,992 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Ocular Therapeutix, Inc. (OCUL) for 27 quarters since Q2 2015.
Renaissance Technologies (RenTech)'s largest addition to Ocular Therapeutix, Inc. (OCUL) was in Q4 2025, adding 791,200 shares worth $9.61 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 1,147,982 shares of Ocular Therapeutix, Inc. (OCUL), valued at approximately $9.72 M.
As of the Q1 2026 filing, Ocular Therapeutix, Inc. (OCUL) represents approximately 0.02% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Ocular Therapeutix, Inc. (OCUL) was 1,147,982 shares, as reported at the end of Q1 2026.